Cas:908494-81-5 3-chloro-N-(3-fluoro-4-methylphenyl)propanamide manufacturer & supplier

Chemical Name:3-chloro-N-(3-fluoro-4-methylphenyl)propanamide

CAS.NO:908494-81-5

Synonyms:3-chloro-N-(3-fluoro-4-methylphenyl)propanamide

Molecular Formula:C₁₀H₁₁ClFNO

Molecular Weight:215.65200

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:353.374ºC at 760 mmHg

Density:1.262g/cm3

Index of Refraction:1.555

PSA:29.10000

Exact Mass:215.05100

LogP:2.77450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-chloro-N-(3-fluoro-4-methylphenyl)propanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-chloro-N-(3-fluoro-4-methylphenyl)propanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-chloro-N-(3-fluoro-4-methylphenyl)propanamide Use and application,3-chloro-N-(3-fluoro-4-methylphenyl)propanamide technical grade,usp/ep/jp grade.

Related News: For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” 3-chloro-N-(3-fluoro-4-methylphenyl)propanamide manufacturer For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” 3-chloro-N-(3-fluoro-4-methylphenyl)propanamide supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 3-chloro-N-(3-fluoro-4-methylphenyl)propanamide vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 3-chloro-N-(3-fluoro-4-methylphenyl)propanamide factory As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth.